PT2575878T - Vacinas compreendendo colesterol e cpg como moléculas únicas adjuvante-portador - Google Patents

Vacinas compreendendo colesterol e cpg como moléculas únicas adjuvante-portador

Info

Publication number: PT2575878T
Authority: PT; Portugal
Prior art keywords: cpg; vaccines; cholesterol; carrier molecules; sole adjuvant
Prior art date: 2010-05-28

Application number

PT11727536T

Other languages

English (en)

Inventor

Lynn Davis Heather

Dhammika Weeratna Risini

Joseph Dominowski Paul

Original Assignee

Zoetis Belgium S A

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2010-05-28

Filing date

2011-05-27

Publication date

2018-10-03

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44626939&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PT2575878(T) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2011-05-27 Application filed by Zoetis Belgium S A filed Critical Zoetis Belgium S A

2018-10-03 Publication of PT2575878T publication Critical patent/PT2575878T/pt

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/099—Bordetella
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/155—Paramyxoviridae, e.g. parainfluenza virus
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/245—Herpetoviridae, e.g. herpes simplex virus
- A61K39/265—Infectious rhinotracheitis virus
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5252—Virus inactivated (killed)
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5254—Virus avirulent or attenuated
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55505—Inorganic adjuvants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/70—Multivalent vaccine
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16711—Varicellovirus, e.g. human herpesvirus 3, Varicella Zoster, pseudorabies
- C12N2710/16734—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
- C12N2760/18534—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18611—Respirovirus, e.g. Bovine, human parainfluenza 1,3
- C12N2760/18634—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/24011—Flaviviridae
- C12N2770/24311—Pestivirus, e.g. bovine viral diarrhea virus
- C12N2770/24334—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/32011—Picornaviridae
- C12N2770/32311—Enterovirus
- C12N2770/32334—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Immunology (AREA)
Virology (AREA)
Epidemiology (AREA)
Mycology (AREA)
Microbiology (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Communicable Diseases (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Pulmonology (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Oncology (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Medicinal Preparation (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Steroid Compounds (AREA)

PT11727536T 2010-05-28 2011-05-27 Vacinas compreendendo colesterol e cpg como moléculas únicas adjuvante-portador PT2575878T (pt)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US34924410P	2010-05-28	2010-05-28

Publications (1)

Publication Number	Publication Date
PT2575878T true PT2575878T (pt)	2018-10-03

Family

ID=44626939

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
PT11727536T PT2575878T (pt)	2010-05-28	2011-05-27	Vacinas compreendendo colesterol e cpg como moléculas únicas adjuvante-portador

Country Status (22)

Country	Link
US (1)	US10456463B2 (pt)
EP (1)	EP2575878B1 (pt)
JP (3)	JP6034285B2 (pt)
KR (1)	KR101528021B1 (pt)
CN (1)	CN103025351B (pt)
AU (2)	AU2011259718B2 (pt)
BR (1)	BR112012030337B1 (pt)
CA (1)	CA2800158C (pt)
CL (1)	CL2012003299A1 (pt)
DK (1)	DK2575878T3 (pt)
ES (1)	ES2683316T3 (pt)
HR (1)	HRP20181039T1 (pt)
HU (1)	HUE038894T2 (pt)
LT (1)	LT2575878T (pt)
MX (1)	MX347471B (pt)
NZ (1)	NZ603527A (pt)
PL (1)	PL2575878T3 (pt)
PT (1)	PT2575878T (pt)
RS (1)	RS57428B1 (pt)
SI (1)	SI2575878T1 (pt)
WO (1)	WO2011148356A1 (pt)
ZA (1)	ZA201208837B (pt)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US8552165B2 (en) *	2008-12-09	2013-10-08	Heather Davis	Immunostimulatory oligonucleotides
CN102333538B (zh) *	2008-12-09	2014-01-15	科勒制药集团有限公司	免疫刺激性寡核苷酸
US8980279B2 (en) *	2010-07-26	2015-03-17	Qu Biologics	Personalized site-specific immunomodulation
US9314519B2 (en) *	2012-08-21	2016-04-19	Intervet Inc.	Liquid stable virus vaccines
MX367268B (es) *	2013-05-14	2019-08-12	Zoetis Services Llc	Nuevas composiciones de vacuna que comprenden oligonucleotidos inmunoestimulantes.
ES2750608T3 (es)	2013-07-25	2020-03-26	Exicure Inc	Construcciones esféricas a base de ácido nucleico como agentes inmunoestimulantes para uso profiláctico y terapéutico
NZ757210A (en) *	2013-09-19	2022-12-23	Zoetis Services Llc	Oil-based adjuvants
RU2016114713A (ru)	2013-10-17	2017-11-20	Зоэтис Сервисиз Ллс	Способы и композиции для лечения s. equi инфекции
BR112016012127A2 (pt) *	2013-11-26	2017-09-26	Zoetis Services Llc	composições para a indução da resposta imunológica
CA2953216C (en)	2014-06-04	2020-12-22	Exicure, Inc.	Multivalent delivery of immune modulators by liposomal spherical nucleic acids for prophylactic or therapeutic applications
AR103427A1 (es) *	2015-01-16	2017-05-10	Zoetis Services Llc	Vacuna contra la fiebre aftosa
RU2736642C2 (ru) *	2015-07-20	2020-11-19	Зоэтис Сервисиз Ллс	Липосомальные адъювантные композиции
US10456459B2 (en) *	2015-07-20	2019-10-29	Zoetis Services Llc	Liposomal adjuvant compositions
CN119097698A (zh)	2015-09-09	2024-12-10	清华大学	作为高效的疫苗佐剂的甲羟戊酸通路的抑制剂
CN107149671B (zh) *	2016-03-03	2021-02-05	郭文江	一种药物组合物及其应用
US11364304B2 (en)	2016-08-25	2022-06-21	Northwestern University	Crosslinked micellar spherical nucleic acids
EP4467565A3 (en)	2016-12-21	2025-03-12	Amgen Inc.	Anti-tnf alpha antibody formulations
WO2018209270A1 (en)	2017-05-11	2018-11-15	Northwestern University	Adoptive cell therapy using spherical nucleic acids (snas)
KR20250048594A (ko)	2017-12-15	2025-04-09	엘랑코 애니멀 헬스 게엄베하	면역자극성 올리고뉴클레오티드
BR112022000347A2 (pt) *	2019-07-12	2022-04-12	Res Found Dev	Vacinas de ehrlichia e composições imunogênicas
TWI884296B (zh) *	2020-08-11	2025-05-21	美商碩騰服務公司	抗冠狀病毒疫苗
IT202100014747A1 (it) *	2021-06-07	2022-12-07	Consiglio Nazionale Ricerche	Derivati sterolici come nuovi ligandi del recettore dectina-1 nel trattamento terapeutico di patologie correlate a tale recettore
CN115645417A (zh) *	2022-10-17	2023-01-31	武汉轻工大学	鹅去氧胆酸在制备治疗或预防猪病毒性腹泻的药物或饲料添加剂中的应用
CN118059219B (zh) *	2024-04-19	2024-06-25	西南交通大学	一种肥胖相关乳腺癌的个性化核酸疫苗及其制备方法

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4469863A (en)	1980-11-12	1984-09-04	Ts O Paul O P	Nonionic nucleic acid alkyl and aryl phosphonates and processes for manufacture and use thereof
ATE75483T1 (de)	1981-10-23	1992-05-15	Molecular Biosystems Inc	Oligonukleotides heilmittel und dessen herstellungsverfahren.
US5023243A (en)	1981-10-23	1991-06-11	Molecular Biosystems, Inc.	Oligonucleotide therapeutic agent and method of making same
DE4321946A1 (de)	1993-07-01	1995-01-12	Hoechst Ag	Methylphosphonsäureester, Verfahren zu deren Herstellung und deren Verwendung
US6239116B1 (en)	1994-07-15	2001-05-29	University Of Iowa Research Foundation	Immunostimulatory nucleic acid molecules
DK0772619T4 (da)	1994-07-15	2011-02-21	Univ Iowa Res Found	Immunmodulatoriske oligonukleotider
US6207646B1 (en)	1994-07-15	2001-03-27	University Of Iowa Research Foundation	Immunostimulatory nucleic acid molecules
GB9718901D0 (en) *	1997-09-05	1997-11-12	Smithkline Beecham Biolog	Vaccine
PT1104306E (pt)	1998-08-10	2006-05-31	Antigenics Inc	Composicoes de cpg e adjuvantes de saponina e seus metodos
FR2783170B1 (fr) *	1998-09-11	2004-07-16	Pasteur Merieux Serums Vacc	Emulsion immunostimulante
GB9921146D0 (en) *	1999-09-07	1999-11-10	Smithkline Beecham Biolog	Novel composition
ATE333284T1 (de)	1999-09-27	2006-08-15	Coley Pharm Group Inc	Verfahren mittels durch nukleinsäuren induziertes immunostimulatorisches interferon
US6949520B1 (en)	1999-09-27	2005-09-27	Coley Pharmaceutical Group, Inc.	Methods related to immunostimulatory nucleic acid-induced interferon
CN1301572A (zh) *	1999-10-28	2001-07-04	上海生物制品研究所	用于疫苗的佐剂组合物
US7129222B2 (en) *	2000-03-10	2006-10-31	Dynavax Technologies Corporation	Immunomodulatory formulations and methods for use thereof
NZ552377A (en)	2001-08-17	2008-08-29	Coley Pharm Gmbh	Combination motif immune stimulatory oligonucleotides with improved activity
GB0123580D0 (en)	2001-10-01	2001-11-21	Glaxosmithkline Biolog Sa	Vaccine
JP4658475B2 (ja) *	2001-11-07	2011-03-23	サイトスバイオテクノロジーアーゲー	骨疾患治療用の抗原アレイ
EP1474432A1 (en) *	2002-02-04	2004-11-10	Biomira Inc.	Immunostimulatory, covalently lipidated oligonucleotides
NZ538628A (en) *	2002-08-12	2008-06-30	Dynavax Tech Corp	Immunomodulatory compositions, methods of making, and methods of use thereof
BRPI0410423A (pt) *	2003-05-07	2006-06-06	Sanofi Pasteur Inc	processo de imunogenicidade melhorada para vacinação meningocócica
AP2006003530A0 (en) *	2003-08-28	2006-02-28	Immune Response Corp Inc	Immunogenic HIV compositions and related methods.
GB0323965D0 (en) *	2003-10-13	2003-11-19	Glaxosmithkline Biolog Sa	Immunogenic compositions
US20050175630A1 (en) *	2003-12-23	2005-08-11	Eyal Raz	Immunogenic compositions and methods of use thereof
US20080254065A1 (en) *	2004-03-09	2008-10-16	Chiron Corporation	Influenza Virus Vaccines
EP1729802A4 (en) *	2004-03-12	2009-12-16	Hybridon Inc	ENHANCED HIV VACCINE ACTIVITY USING SECOND GENERATION IMMUNOMODULATORY OLIGONUCLEOTIDE
CA2574090A1 (en) *	2004-07-18	2006-12-21	Coley Pharmaceutical Group, Ltd.	Methods and compositions for inducing innate immune responses
WO2006056142A1 (en) *	2004-11-29	2006-06-01	Changchun Huapu Biotechnology Co., Ltd.	Cpg single-strand deoxynucleotides for use as adjuvant
EP1849780A1 (en) *	2006-04-21	2007-10-31	De Staat der Nederlanden, vert. door de minister van VWS	Vaccine against nicotine addiction
CA2653939C (en) *	2006-05-31	2013-01-22	Toray Industries, Inc.	Immunostimulatory oligonucleotides and use thereof in pharmaceuticals
MX2009003398A (es)	2006-09-27	2009-08-12	Coley Pharm Gmbh	Analogos de oligonucleotidos cpg que contienen analogos t hidrofobos con actividad inmunoestimuladora mejorada.
CA2687441A1 (en) *	2007-05-17	2008-11-27	Coley Pharmaceutical Group, Inc.	Class a oligonucleotides with immunostimulatory potency
US20110038941A1 (en) *	2007-12-27	2011-02-17	The Ohio State University Research Foundation	Lipid Nanoparticle Compositions and Methods of Making and Using the Same
NZ621834A (en)	2008-06-27	2015-10-30	Zoetis Services Llc	Novel adjuvant compositions

2011
- 2011-05-27 CN CN201180036906.3A patent/CN103025351B/zh active Active
- 2011-05-27 MX MX2012013731A patent/MX347471B/es active IP Right Grant
- 2011-05-27 PT PT11727536T patent/PT2575878T/pt unknown
- 2011-05-27 EP EP11727536.2A patent/EP2575878B1/en active Active
- 2011-05-27 SI SI201131538T patent/SI2575878T1/sl unknown
- 2011-05-27 PL PL11727536T patent/PL2575878T3/pl unknown
- 2011-05-27 BR BR112012030337-6A patent/BR112012030337B1/pt active IP Right Grant
- 2011-05-27 CA CA2800158A patent/CA2800158C/en active Active
- 2011-05-27 LT LTEP11727536.2T patent/LT2575878T/lt unknown
- 2011-05-27 NZ NZ603527A patent/NZ603527A/en unknown
- 2011-05-27 WO PCT/IB2011/052347 patent/WO2011148356A1/en not_active Ceased
- 2011-05-27 AU AU2011259718A patent/AU2011259718B2/en active Active
- 2011-05-27 KR KR1020127033947A patent/KR101528021B1/ko active Active
- 2011-05-27 ES ES11727536.2T patent/ES2683316T3/es active Active
- 2011-05-27 HU HUE11727536A patent/HUE038894T2/hu unknown
- 2011-05-27 JP JP2013513022A patent/JP6034285B2/ja active Active
- 2011-05-27 RS RS20180784A patent/RS57428B1/sr unknown
- 2011-05-27 HR HRP20181039TT patent/HRP20181039T1/hr unknown
- 2011-05-27 JP JP2011118735A patent/JP2011251963A/ja not_active Withdrawn
- 2011-05-27 DK DK11727536.2T patent/DK2575878T3/en active
- 2011-05-27 US US13/699,997 patent/US10456463B2/en active Active
2012
- 2012-11-22 ZA ZA2012/08837A patent/ZA201208837B/en unknown
- 2012-11-26 CL CL2012003299A patent/CL2012003299A1/es unknown
2016
- 2016-05-31 AU AU2016203611A patent/AU2016203611B2/en active Active
- 2016-09-06 JP JP2016173482A patent/JP6133482B2/ja active Active

Also Published As

Publication number	Publication date
EP2575878A1 (en)	2013-04-10
MX347471B (es)	2017-04-24
NZ603527A (en)	2014-10-31
HUE038894T2 (hu)	2018-12-28
US10456463B2 (en)	2019-10-29
CN103025351A (zh)	2013-04-03
RS57428B1 (sr)	2018-09-28
JP6133482B2 (ja)	2017-05-24
WO2011148356A1 (en)	2011-12-01
EP2575878B1 (en)	2018-06-13
JP2013532140A (ja)	2013-08-15
AU2011259718B2 (en)	2016-03-03
JP2017048187A (ja)	2017-03-09
CN103025351B (zh)	2016-08-24
JP6034285B2 (ja)	2016-11-30
LT2575878T (lt)	2018-11-12
CA2800158C (en)	2020-07-21
JP2011251963A (ja)	2011-12-15
PL2575878T3 (pl)	2018-12-31
MX2012013731A (es)	2013-12-16
BR112012030337A2 (pt)	2017-01-24
SI2575878T1 (sl)	2018-12-31
ES2683316T3 (es)	2018-09-26
KR20130069668A (ko)	2013-06-26
KR101528021B1 (ko)	2015-06-10
US20130084306A1 (en)	2013-04-04
BR112012030337B1 (pt)	2021-04-27
CA2800158A1 (en)	2011-12-01
HRP20181039T1 (hr)	2018-08-24
ZA201208837B (en)	2013-08-28
AU2011259718A1 (en)	2012-12-06
AU2016203611B2 (en)	2017-06-15
AU2016203611A1 (en)	2016-06-16
DK2575878T3 (en)	2018-08-13
CL2012003299A1 (es)	2013-03-08

Publication	Publication Date	Title
ZA201208837B (en)	2013-08-28	Vaccines comprising cholesterol and cpg as sole adjuvant-carrier molecules
ZA201307844B (en)	2015-12-23	Influenza nucleic acid molecules and vaccines made therefrom
GB201010557D0 (en)	2010-08-11	RNA molecules and uses thereof
IL223206A0 (en)	2013-02-03	Vaccine formulations
GB201005005D0 (en)	2010-05-12	New vaccine
PL2796150T3 (pl)	2021-08-30	Nowe koniugaty oligonukleotydowe i ich zastosowanie
EP2855769A4 (en)	2016-03-02	PAPER-MOUCHOIR COMPRISING MACROALGUES
IL237865B (en)	2021-04-29	Compositions of naturally occurring cpg oligonucleotides and their medical applications
EP2654872A4 (en)	2014-05-07	AUTODILATION CANNULA
GB201014965D0 (en)	2010-10-20	Vaccine
GB201003293D0 (en)	2010-04-14	Cancer vaccine
PL2750645T3 (pl)	2018-04-30	Medyczna pończocha podpierająca i uciskowa
EP2558506A4 (en)	2013-08-14	GEWEBEANZIELUNG
PL2536400T3 (pl)	2015-04-30	Lek zawierający miramistin
PL3097920T3 (pl)	2020-03-31	Kompozycja medyczna zawierająca ekstrakt stauntonia hexaphylla
GB201013006D0 (en)	2010-09-15	Vaccine
GB201006324D0 (en)	2010-06-02	Vaccine
EP2609539A4 (en)	2015-07-15	VIRTUAL HOT CONNECTION TECHNIQUES
ZA201302154B (en)	2014-08-27	Vaccine
GB201007588D0 (en)	2010-06-23	Vaccine
GB201007589D0 (en)	2010-06-23	Vaccine
GB201012283D0 (en)	2010-09-08	Vaccine
GB201009277D0 (en)	2010-07-21	Novel vaccine
GB201008795D0 (en)	2010-07-14	Vaccines
GB201008793D0 (en)	2010-07-14	vaccines